DVA Quote, Financials, Valuation and Earnings

Healthcare Services Group has a net margin of 5.05% compared to DaVita's net margin of 3.85%. DaVita's return on equity of 38.96% beat Healthcare Services Group's return on equity of 8.45%.

DaVita has a consensus price target of $159.15, signalling upside risk potential of 13.5%. On the other hand Healthcare Services Group has an analysts' consensus of $15.00 which suggests that it could grow by 13.64%. Given that Healthcare Services Group has higher upside potential than DaVita, analysts believe Healthcare Services Group is more attractive than DaVita.

DaVita has a beta of 1.106, which suggesting that the stock is 10.596% more volatile than S&P 500. In comparison Healthcare Services Group has a beta of 0.566, suggesting its less volatile than the S&P 500 by 43.375%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healthcare Services Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DaVita pays -- of its earnings as a dividend. Healthcare Services Group pays out -- of its earnings as a dividend.

DaVita quarterly revenues are $3.2B, which are larger than Healthcare Services Group quarterly revenues of $447.7M. DaVita's net income of $162.9M is higher than Healthcare Services Group's net income of $17.2M. Notably, DaVita's price-to-earnings ratio is 13.90x while Healthcare Services Group's PE ratio is 23.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 0.92x versus 0.56x for Healthcare Services Group. Usually stocks with elevated PS ratios are considered overvalued.

Select Medical Holdings has a net margin of 5.05% compared to DaVita's net margin of 4.19%. DaVita's return on equity of 38.96% beat Select Medical Holdings's return on equity of 8.92%.

DaVita has a consensus price target of $159.15, signalling upside risk potential of 13.5%. On the other hand Select Medical Holdings has an analysts' consensus of $20.50 which suggests that it could grow by 40.89%. Given that Select Medical Holdings has higher upside potential than DaVita, analysts believe Select Medical Holdings is more attractive than DaVita.

DaVita has a beta of 1.106, which suggesting that the stock is 10.596% more volatile than S&P 500. In comparison Select Medical Holdings has a beta of 1.325, suggesting its more volatile than the S&P 500 by 32.536%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Select Medical Holdings offers a yield of 1.78% to investors and pays a quarterly dividend of $0.06 per share. DaVita pays -- of its earnings as a dividend. Select Medical Holdings pays out 30.19% of its earnings as a dividend. Select Medical Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DaVita quarterly revenues are $3.2B, which are larger than Select Medical Holdings quarterly revenues of $1.4B. DaVita's net income of $162.9M is higher than Select Medical Holdings's net income of $56.7M. Notably, DaVita's price-to-earnings ratio is 13.90x while Select Medical Holdings's PE ratio is 10.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 0.92x versus 0.38x for Select Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Surgery Partners has a net margin of 5.05% compared to DaVita's net margin of -4.86%. DaVita's return on equity of 38.96% beat Surgery Partners's return on equity of -5.45%.

DaVita has a consensus price target of $159.15, signalling upside risk potential of 13.5%. On the other hand Surgery Partners has an analysts' consensus of $31.36 which suggests that it could grow by 38.53%. Given that Surgery Partners has higher upside potential than DaVita, analysts believe Surgery Partners is more attractive than DaVita.

DaVita has a beta of 1.106, which suggesting that the stock is 10.596% more volatile than S&P 500. In comparison Surgery Partners has a beta of 1.896, suggesting its more volatile than the S&P 500 by 89.589%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Surgery Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DaVita pays -- of its earnings as a dividend. Surgery Partners pays out -- of its earnings as a dividend.

DaVita quarterly revenues are $3.2B, which are larger than Surgery Partners quarterly revenues of $776M. DaVita's net income of $162.9M is higher than Surgery Partners's net income of -$37.7M. Notably, DaVita's price-to-earnings ratio is 13.90x while Surgery Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 0.92x versus 0.90x for Surgery Partners. Usually stocks with elevated PS ratios are considered overvalued.

US Physical Therapy has a net margin of 5.05% compared to DaVita's net margin of 6.97%. DaVita's return on equity of 38.96% beat US Physical Therapy's return on equity of 4.62%.

DaVita has a consensus price target of $159.15, signalling upside risk potential of 13.5%. On the other hand US Physical Therapy has an analysts' consensus of $106.00 which suggests that it could grow by 43.77%. Given that US Physical Therapy has higher upside potential than DaVita, analysts believe US Physical Therapy is more attractive than DaVita.

DaVita has a beta of 1.106, which suggesting that the stock is 10.596% more volatile than S&P 500. In comparison US Physical Therapy has a beta of 1.442, suggesting its more volatile than the S&P 500 by 44.202%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. US Physical Therapy offers a yield of 2.41% to investors and pays a quarterly dividend of $0.45 per share. DaVita pays -- of its earnings as a dividend. US Physical Therapy pays out 100.3% of its earnings as a dividend.

DaVita quarterly revenues are $3.2B, which are larger than US Physical Therapy quarterly revenues of $183.8M. DaVita's net income of $162.9M is higher than US Physical Therapy's net income of $12.8M. Notably, DaVita's price-to-earnings ratio is 13.90x while US Physical Therapy's PE ratio is 33.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 0.92x versus 1.59x for US Physical Therapy. Usually stocks with elevated PS ratios are considered overvalued.